



9p 164
Docket No. 21US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Wang et al.

Application No: 09/528,225

Filing Date: March 21, 2000

For: CHIMERIC PROTEINS FOR DIAGNOSIS AND
TREATMENT OF DIABETES

Mail Stop Patent Application
Commissioner for Patents

P.O. Box 1450
Alexandria, VA 22313-1450


CERTIFICATE OF MAILING

Date of Deposit: March 16, 2004

I hereby certify that the following:

- This Certificate of Mailing
- Information Disclosure Statement
- Form PTO-1449
- Cited art
- Return receipt postcard

are being deposited with the United States Postal Service first-class mail on the Date of Deposit indicated above in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.


Lori Rooney

Mark Farber
C/O
Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410



Docket: 21 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Wang et al.

Serial No: 09/528,225

Examiner: Saoud, Christine J.

Filed: March 21, 2000

Group Art Unit: 1647

For: Chimeric Proteins for Diagnosis and Treatment of Diabetes

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's duty of disclosure under 37 C.F.R. §1.56, Applicants submit the enclosed reference for the Examiner's consideration.

It is respectfully requested that the reference(s) submitted with Form PTO-1449 be considered during Examination of the above-identified application and made of record therein. A copy of the reference(s) is/are enclosed. This submission is believed to be in compliance with 37 C.F.R. §1.97 and 37 C.F.R. §1.98.

The citation of the listed item(s) is not a representation that it constitutes a complete or exhaustive listing of prior art or that it constitutes prior art. The item(s) listed is/are submitted in good faith, but is/are not intended to substitute for the Examiner's search. It is hoped, however, that in addition to apprising the Examiner, it will assist the Examiner in identifying fields of search and in making as full and complete a search as possible.

The filing of this information disclosure statement is not an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

This information disclosure statement is being filed within three (3) months of the filing date of this application.

This information disclosure statement is being filed within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application.

To the best of Applicant(s) knowledge, this information disclosure statement is being filed before the date of mailing of a first Office Action in connection with this case.

Enclosed is a certificate under 37 C.F.R. §1.97 (e) (i).

() Enclosed is a petition under 37 C.F.R. §1.97 (d)

() Please charge the petition fee of \$130.00 required under 37 C.F.R. §1.17 (i)(1) to Deposit Account No. 01-0483.

(x) This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection of Notice of Allowance

() Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97 (e) (1); and no fee is required under 37 C.F.R. §1.17 (p).

() As set forth in 37 C.F.R. §1.97 (c), to the best of Applicant(s) knowledge, this information disclosure statement is being filed before either the mailing of a final action under 37 C.F.R. §1.113 or the mailing of a notice of allowance under 37 C.F.R. §1.113, and is accompanied by the \$220.00 fee as provided for in 37 C.F.R. §1.17(p).

() Please charge the \$240.00 fee required by 37 C.F.R. §1.17(p) to Deposit Account No. 01-0483.

(x) Please charge any deficiency as well as any other fee(s) which may become due under 37 C.F.R. §1.16 and/or 37 C.F.R. §1.17 at any time during the pendency of this application, or credit any overpayment of such fee(s) to Deposit Account 01-0483. Also, in the event any extensions of time for responding are required for the pending application(s), please treat this paper as a petition to extend time as required and charge Deposit Account No. 01-0483 therefor. TWO COPIES OF THIS SHEET ARE ENCLOSED.

Early and favorable consideration of the case is respectfully requested.

Dated: March 16, 2004



Mark Farber
Registration No. 34,159
Attorney for Applicants

Mark Farber
C/O
Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410
(203) 271-8319



Sheet ___ of ___


Form PTO-1449 U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		
(Use several sheets if necessary)		
	APPLICANT	
	FILING DATE	GROUP Art Unit:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Ammerer, 1983. Meth Enzymol 101:192
	Atkinson and Maclaren, 1993 J Clin Invest 92:1608-1616
	Atkinson et al. 1990 Lancet 335:1357-1360
	Atkinson et al. 1990 Diabetes 39:933-937
	Atkinson et al. 1992 Lancet 339:458-459
	Atkinson et al. 1993 J Clin Invest 91:350-356
	Ausubel et al. 1994 Current Protocols In Molecular Biology, John Wiley & Sons, New York
	Baekkeskov et al. 1982 Nature 298:167-169
	Baekkeskov et al. 1987 J Clin Invest 79:926-934
	Baekkeskov et al. 1990 Nature 347:151-156
	Bock et al. 1992 Lancet 339:1504-1506
	Boehme and Leardo 1993 Eur J Immunol 23:1552+1560
	Bonifacio et al. 1990 Lancet 335:147-149
	Bowman et al. 1994 Immunol Today 15 (3):115-120
	Brunner et al. 1995 Nature 373:441-444
	Butler et al. 1993 J Exp Med 178:2097-2106
	Chang et al. 1978 Nature 275:615 et seq,
	Chen et al. 1994 Science 265:1237-1240
	Chou 1990 Prediction of Protein Stature and the Principles of protein Conformation Plenum Press 549-586
	Chou and Fasman 1978 Adv Enzymol 47:45-147
	Cohen et al. 1992 Ann Rev Immunol 10:267 et seq.
	Coligen et al. 1995 Current Protocols in Immunology John Wiley & Sons, New York
	Conrad et al. 1994 Nature 371:351-355
	Cotter et al. 1990 Anticancer Research 10:1153 et seq.
	Crispe 1994 Immunity 1:347-349
	Danielet et al. Proc Natl. Acad. Sci. USA 93:956-960
	Davis et al. Basic Methods in Molecular Biology, 2 nd ed. Appleton and Large Norwalk, CT
	De Aizpurua et al. 1992 Proc Natl Acad Scie USA 89:9841-9845
	Dhein et al. 1995 Nature 373:438-441
	Duvall and Wyllie 1986 Immunol Today 7:115 et seq.
	Elliott et al. 1996 J Clin Invest 98:1-11

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet ___ of ___

Form PTO-1449 U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		
(Use several sheets if necessary)		
	APPLICANT	
	FILING DATE	GROUP Art Unit:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Evans and Scarpulla 1989 Gene 84:135 et seq.
	Farrell, Jr. 1993 RNA Methodologies: A Laboratory Guide For Isolation And Characterization. Academic Press Inc. San Diego, CA
	Foster 1994 Harrison's Principles of Int Med, Thirteenth Ed., McGraw-Hill, New York, pp 1979-2000
	Garnier et al., 1978 J Mol Biol 120:97-120
	Goeddel et al., 1980 Nucl Acids Res 8:4057 et seq.
	Griffin and Griffin, Eds., 1994 PCR Technology, Current Innovations. CRC Press, Boca Raton, FL
	Griffin et al., 1995 Am J. Pathol 147:845-857
	Grosjean and Fiers, 1982 Gene 18:199 et seq.
	Hanninen et al., 1992 J Clin Invest 90:1901-1910
	Harrison, 1992 Immunol Today 13:348-352
	Harwood, Ed., 1994 Protocols For Gene Analysis: Methods In Molecular Biology, Vol. 31. The Humana Press, Totowa, NJ.
	Hatfield et al. 1997 Diabetologia 40:1327-1333
	Hernan et al., 1992 Biochemistry 31:8619 et seq.
	Herold et al., 1992 J Exp Med 176:1107-1114
	Ho et al. 1989 Gene 77:51-59
	Honeyman et al., 1993 J Exp Med 177:353-340
	Huang and Gorman, 1990 Mol Cell Biol 10:1805 et seq.
	Ju et al. 1995 Nature 373:444-448
	Karjalainen et al., 1992 New Eng J Med 327:302-307
	Karounos and Thomas 1990 Nature 39:1085-1090
	Kaufman et al. 1992 J Clin Invest 98:283-292
	Kaufman et al., 1993 Nature 366:69-72
	Kaufman et al., 1993 Nature 366:69-71
	Kawabe and Ochi, 1991 Nature 349:245-248
	Kawasaki et al., 1997 J. Clin. Endocrinol. Metab 82:375-380
	Kerr et al., 1991 Apoptosis: The Molecular Basis of Cell Death, Tomei and Cope (eds.), Cold Spring Laboratory Press, Plainview, New York pp 5 et seq.
	Kim et al., 1993 Immunol Invest 22(3):219-227
	Klaus, ed. 1987 Lymphocytes: A Practical Approach IRL Press Oxford England
	Lenardo, 1991 Nature 353:858-860
	Locksley and Zekeri, 1991 Apoptosis: The Molecular Basis of Cell Death, Tomei and Cope (eds), Cold Spring Harbor Laboratory Press, Planview, New York, pp 47 et seq.
	Lohman et al., 1994 Lancet 343:1607-1608

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet ___ of ___


Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		
(Use several sheets if necessary)		
	APPLICANT	
	FILING DATE	GROUP Art Unit:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Lohman et al., 1996 J of Autoimmunity 9:385-389
	Lohman et al., 1996 Hormone & Metabolic Res. 28:357-360
	Luckow et al., 1988 Bio/Technology 6:47 et seq.
	MacLaren, N and K Laffety 1993 Diabetes 42:1099-1104
	Maniatis, 1982 Molecular Cloning: A Laboratory Manual
	Marrack and Kappler, 1987 Science 238:1073 et seq.
	Moir, et al. 1991 Meth Enzymol 194:491-507
	Morgenstern and Land 1990 Nucl Acids Res 18:3587 et seq.
	Muir et al., 1995 J Clin Invest 95, pp628-634
	Mullis et al., Eds., 1994 The Polymerase Chain Reaction Springer-Verlag, New York, NY
	Nagata and Suba, 1995 Immunol Today 16:39 et seq.
	Naquet et al., 1988 J Immunol 140:2569-2578
	Nossal et al., 1992 Diabetologia pp 549-559
	Ormerod, Ed., 1994 Flow Cytometry: A Practical Approach 2 nd ed. IRL Press at Oxford University Press Oxford England.
	Paul, 1989 Fundamental Immunology 2 nd ed Paul (ed) Raven Press, New York
	Quinn, A and E.E. Sercarz 1996 J Autoimmunity 9:365-370
	Ramiya et al., 1996 J. Autoimmunity 9:349-356
	Remington's Pharmaceutical Science, Mack Publishing Co., Philadelphia PA 17 th ed (1985)
	Richter et al., 1992 Proc Natl Acad Sci USA 89:8467-8471
	Rudy et al., 1995 Mol Medicine 1:625-633
	Russell et al., 1993 Proc Natl Acad Sci USA 90:4409-4413
	Sambrook et al., 1990 Molecular Cloning: A Laboratory Manual Cold Spring Harbor Press Cold Spring Harbor NY
	Sato et al., 1994 J Biol Chem 269:17267 et seq.
	Schena et al., 1991 Meth Enzymol 194:389-398
	Schwartz, 1993 Schwartz, RS, Immunolgy 3 rd ed. Raven Press New York, 1993 pp 1033-1097
	Sercarz et al., 1959 Nature 184:1080-1082
	Singer et al., 1994 Immunity 1:365-371
	Smith et al., 1989 Nature 337:181-184
	Solimena and De Camilli, 1993 Nature 366: 15-17
	Steinman, 1995 Cell 80:7-10
	Strasser, 1995 Nature 373:385-386

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet ___ of ___

Form PTO-1449 U.S. DEPARTMENT OF
COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

SERIAL NO.

APPLICANT

FILING DATE

GROUP Art Unit:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Sun et al., Eur J Immunol 21:1461-1468
Taguchi et al., 1990 J Immunol Meth 128:65-73
Talib et al., 1991 Gene 98:289-293
Tisch et al., 1993 Nature 366:72-75
Von Boehmer, 1988 Ann Rev Immunol 6:309 et seq.
Waslston et al., 1995 N Eng J Med 333:343-347
Walter et al., 1994 J Clin Invest 8:163-166
Weir, 1978 Handbook Of Experimental Immunology 3rd ed. Volume 2, Cellular
Immunology Blackwell Scientific Publication Oxford England
Wicker et al., 1996 J Clin Invest 98:2597-2603
Williams et al., 1988 Nucl Acids Res 16:10453 et seq.
Wong et al., 1998 J. Clin Invest 102:947-957
Xie et al., 1997 J Immunol 159:3662-3667
Zhang et al., 1997 Diabetes 46:40-43
Zhang et al., 1991 Proc Natl Acad Sci USA 88:10252-10256

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner
Initial

OTHER ART

— ABBAS, et al. 1994 Cell Mol Immunol 376-392

— ABO, S et al. 1993 Bio Molec Biol Int 30:945-958
Preparation of Highly Purified Human Myelin Oligodendrocyte Glycoprotein In Quantities Sufficient For Encephalitogenicity And Immunogenicity Studies.

— ADORINI, L et al. 1993 Immunol Today 14:285-289
Selective Immunosuppression.

— ALLEGRETTA, M et al. 1990 Science 247:718-722
T Cells Responsive to Myelin basic Protein in Patients with Multiple Sclerosis.

— ALLEGRETTA, M et al. 1994 J Clin Invest 94:105-109
Homologies Between T Cell Receptor Junctional Sequences Unique To Multiple Sclerosis And T Cells Mediating Experimental Allergic Encephalomyelitis.

— ALVORD, EC et al. 1979 Ann Neurol 6:461-468
Has Myelin Basic Protein Received a Fair Trial in the Treatment of Multiple Sclerosis?

— ALVORD, EC et al. 1979 Ann Neurol 6:469-473 Myelin Basic Protein Treatment Of Experimental Allergic Encephalomyelitis in Monkeys

— AMOR S, et al. 1994 Journal of Immunology 153:4349-4356
Identification of Epitopes of Myelin Oligodendrocyte Glycoprotein for the Induction of Experimental Allergic Encephalomyelitis in SJL and Biozzi AB/H Mice.

— ARUGA, J et al. 1991 J Neurochem 56:1222-1226 Identification of the New Isoforms of Mouse Myelin Basic Protein: The Existence Of Exon 5a.

— BARNETT, LA et al. 1993 J Neuroimmunol 44:15-26
Enhancement Of Autoimmune Disease Using Recombinant Vaccinia Virus Encoding Myelin Proteolipid Protein.

— BISHOPP, F. 1997 Bioworld Today 8 (77): 1
Autoimmune Stock Sinks on Disappointing Phase III Myloral Trial Data in MS.

— BOEHME, S et al. 1993. Eur J Immunol 23:1552-1560
Propriocidal Apoptosis of Mature T Lymphocytes Occurs at S Phase of the Cell Cycle.

— CARNEGIE P, et al. 1971 Biochem J 123:57-67
Amino Acid Sequence of the Encephalitogenic Basic Protein

— CHEN, Y et al. 1994 Science 265:1237-1240
Regulatory T Cell Clones Induced by Oral Tolerance: Suppression of Autoimmune Encephalomyelitis.

Examiner
Initial

OTHER ART

— CHIANG, B-L et al. 1992 Int Arch Allergy Immunol 98:181-188
Prospects of Vaccination in Autoimmune Diseases.

— CHOU, YK et al. 1991 J Neurosci Res 28:280-290
Specificity of Human T Cell Clones Reactive to Immunodominant Epitopes of Myelin Basic Protein.

— CHOU, YK et al. 1992. J Neuroimmunol 38:105-114
Frequency Of T Cells Specific For Myelin Basic Protein And Myelin Proteolipid Protein In Blood And Cerebrospinal Fluid In Multiple Sclerosis.

— CORREALE, J et al. 1995 J Immunology 154:2959-2968
Patterns of Cytokine Secretion by Autoreactive Proteolipid Protein-Specific T Cell Clones During the Course of Multiple Sclerosis.

— CRITCHFIELD, JM et al. 1994 Science 263:1139-1143
T Cell Deletion in High Antigen Dose Therapy of Autoimmune Encephalomyelitis.

— DIEHL H, et al. 1986 Proc. Natl. Acad. Sci. USA 83:9807-9811
Individual exons encode the integral membrane domains of human myelin proteolipid protein.

— DUVALL, et al. 1986 Immunol Today 7:115-119

— EINSTEIN, et al. 1962 J Neurochem 9:353-361
The isolation from bovine spinal cord of a homogeneous protein with encephalitogenic activity.

— ENDOH, M et al. 1986 J Immunol 137:3832-3835
DM-20, A Proteolipid Apoprotein, Is An Encephalitogen Of Acute And Relapsing Autoimmune Encephalomyelitis In Mice.

— FRITZ, RB et al. 1994 J Neuroimmunol 51:1-6
Encephalitogenicity Of Myelin Basic Protein Exon-2 Peptide In Mice.

— GREER, JM et al. 1992 J Immunol 149:783-788
Identification and Characterization of a Second Encephalitogenic Determinant of Myelin Proteolipid Protein (Residues 178-191) for SJL Mice.

— GRIMA, B et al. 1992 J Neurochem 59:2318-2323
A Novel Transcript Overlapping the Myelin Basic Protein Gene.

— GROSJEAN, H et al. 1982 Gene 18:199-209
Preferential Codon Usage In Prokaryotic Genes: The Optimal Codon-Anticodon Interaction Energy And The Selective Codon Usage In Efficiently Expressed Genes.

Examiner
Initial

OTHER ART

— HERNAN, RA et al. 1992 Biochemistry 31:8619-8628
Human Hämoglobin Expression In Escherichia Coli: Importance Of Optimal Codon Usage.

— HIGGINS, PAUL J. et al. 1988 J Immunol 140:440-445.
Suppression Of Experimental Autoimmune Encephalomyelitis by Oral Administration of Myelin Basic Protein and its Fragments.

— HORVATH, L et al. 1990 Biochemistry 29:2635-2638
Influence of Polar residue Deletions of Lipid-Protein Interactions with the Myelin Proteolipid Protein. Spin-Label ESR Studies with DM-20/Lipid Recombinants.

— JOHNSON, D et al. 1986 J Neuroimmunol 13:99-108
Cell-Mediated Immunity to Myelin-Associated Glycoprotein, Proteolipid Protein, and Myelin Basic Protein in Multiple Sclerosis.

— KAMHOLZ, J et al. 1986 Proc Natl Acad Sci USA 83:4962-4966
Identification of three forms of human myelin basic protein by cDNA cloning.

— KAMHOLZ, J et al. 1988 J Neurosci Res 21:62-70
Organization and Expression of the Human Myelin Basic Protein Gene.

— KAUFMAN, DL et al. 1993 Nature 366:69-72
Spontaneous Loss Of T-Cell Tolerance To Glutamic Acid Decarboxylase In Murine Insulin-Dependent Diabetes.

— KENNEDY, M et al. 1990 J Immunol 144: 909-915
Inhibition of Murine Relapsing Experimental Autoimmune Encephalomyelitis by Immune Tolerance to Proteolipid Protein and its Encephalitogenic Peptides.

— KERLERO DE ROSBO, et al. 1993 J Clin Invest 92:2602-2608 Reactivity to Myelin Antigens in Multiple Sclerosis.

— KRONQUIST, et al. 1987 J Neurosci Res 18:395-401
Expression of Myelin Proteins in the Developing Human Spinal Cord: Cloning and Sequencing of Human Proteolipid Protein cDNA.

— LEHMANN, PV et al. 1992 Nature 358:155-157
Spreading Of T-Cell Autoimmunity To Cryptic Determinants Of An Autoantigen.

Examiner
Initial

OTHER ART

LIBLAU, R et al. 1991 Eur J Immunol 21:1391-1395
T Cell Response To Myelin Basic Protein Epitopes In Multiple Sclerosis Patients
And Healthy Subjects.

MARTIN, R et al. 1992 Ann Rev Immunol 10:153-187
Immunological Aspects of Demyelinating Diseases.

MARTIN, R et al. 1992 J Immunol 148:1359-1366
Diversity in Fine Specificity and T Cell Receptor Usage of the Human CD4+
Cytotoxic T Cell Response Specific for the Immunodominant Myelin Basic Protein
Peptide 87-106.

MCRAE, B et al. 1992 J Neuroimmunol 38:229-240
Induction Of Active And Adoptive Relapsing Experimental Autoimmune
Encephalomyelitis (EAE) Using An Encephalitogenic Epitope Of Proteolipid
Protein.

MEINL, et al. 1993 J Clin Invest 92:2633-2643
Myelin Basic Protein-Specific T Lymphocyte Repertoire in Multiple Sclerosis.

MILLER, A et al. 1992 J Neuroimmunol 39:243-250
Suppression Of Experimental Autoimmune Encephalomyelitis By Oral
Administration Of Myelin Basic Protein. V. Hierarchy Of Suppression By Myelin
Basic Protein From Different Species.

MILLER, A et al. 1992 Neurology 42(suppl 3):301 et seq.
Active suppression Versus Clonal Anergy Following Oral or IV Administration of
MBP in Actively and Passively Induced EAE.

MILLER, A et al. 1992 Proc. Natl. Acad. Sci. USA 89:421-425
Suppressor T Cells generated by oral tolerization to myelin basic protein suppress
both in vitro and in vivo immune responses by the release of transforming growth
factor after antigen-specific triggering.

MILLER, SD et al. 1994 Immunol Today 15:356-361
The Immunopathogenesis And Regulation Of T-Cell-Mediated Demyelinating
Diseases.

MITCHISON 1964 Proc R Soc London Ser B 161:275-280
Induction of immunological paralysis in two zones of dosage.

OETTINGER, H et al. 1993 J Neuroimmunol 44:157-162.
Biological Activity Of Recombinant Human Myelin Basic Protein.

Examiner
Initial

OTHER ART

PELFRY, et al. 1993 J Neuroimmunol 46:33-42
Identification of a novel T cell epitope of human proteolipid protein (residues 40-60) recognized by proliferative and cytolytic CD4+ T cells from multiple sclerosis patients.

PELFRY, et al. 1994 J Neuroimmunol 53:153-161
Identification of a second T cell epitope of human proteolipid protein (residues 89-106) recognized by proliferative and cytolytic CD4+ T cells from multiple sclerosis patients.

PEREYRA, P et al. 1988 Neurochem Res 13: 583-595
Triton X-100 Extractions of Central Nervous System Myelin Indicate a Possible Role for the Minor Myelin Proteins in the Stability of Lamellae.

PETTE, M et al. 1990 Neurology 40:1770
Myelin Basic Protein-Specific T Lymphocyte Lines From MS Patients And Healthy Individuals.

PHAM-DINH, D et al. 1994 J Neurochem 63:2353-2356.
Characterization and Expression of the cDNA Coding for the Human Myelin/Oligodendrocyte Glycoprotein.

POPOP J, et al. 1991 J. Memb. Biol. 120:233-246
Major Myelin Proteolipid: The 4 Alpha-Helix Topology.

PROOST P, et al. 1993 Bioch. Biophys. Res. Com. 192:1175-1181
Leukocyte Gelatinase B Cleavage Releases Encephalitogens from Human Myelin Basic Protein.

QIN, Y et al. 1989 Eur J Immunol 19:373-380
Resistance To Experimental Autoimmune Encephalomyelitis Induced By Neonatal Tolerization To Myelin Basic Protein: Clonal Elimination Vs. Regulation Of Autoaggressive Lymphocytes.

RACKE MK et al. 1995 J Immunol 154:450-458
Retinoid Treatment of Experimental Allergic Encephalomyelitis - IL-4 Production Correlates with Improved Disease Course

RAINE, C. 1985 Handbook of Clinical Neurology 3 (47):429-466 Koetsier (ed)
Elsevier Science Publishers

RICHERT JR et al. 1989. J Neuroimmunol 23:55-66
Evidence for multiple human T cell recognition sites on myelin basic protein.

ROTH, HJ et al. 1987 J Neurosci Res 17:321-328
Evidence for the Expression of Four Myelin Basic Protein Variants in the Developing Human Spinal Cord through cDNA Cloning.

Examiner
Initial

OTHER ART

— SAEKI, Y et al. 1992 Proc Natl Acad Sci USA 89:6157-6161
Transfer Of Multiple Sclerosis Into Severe Combined Immunodeficiency Mice By Mononuclear Cells From Cerebrospinal Fluid Of The Patients

— SAKAI, et al. 1989 Proc Natl Acad Sci 86:9470-9474
Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins.

— SALVETTI, M et al. 1993 Eur J Immunol 23:1232-1239
Predominant And Stable T Cell Responses To Regions Of Myelin Basic Protein Can Be Detected In Individual Patients With Multiple Sclerosis.

— SCHWARTZ, 1993 Fundamental Immunology, 3rd Ed. 1033-1083

— SEGAL, et al. 1994 J Neuroimmunol 51:7-19
Experimental Allergic Encephalomyelitis Induced By The Peptide Encoded By Exon 2 Of The MBP Gene, A Peptide Implicated In Remyelination.

— SERCARZ et al. 1959 Nature 184:1080-1082
Specific Inhibition of Antibody Formation During Immunological Paralysis and Unresponsiveness.

— SHPAER, E. 1986 J Mol Biol 188:555-564
Constraints on Codon Context in Escherichia coli Genes, Their Possible Role in Modulating the Efficiency of Translation.

— SOBEL RA et al. 1994 Neurochem Res 19:915-921
Minireview: Autoimmune Responses to Myelin Proteolipid Protein.

— SRIRAM, S et al. 1983 Cell Immunol 75:378-382
Administration Of Myelin Basic Protein-Coupled Spleen Cells Prevents Experimental Allergic Encephalitis.

— STREICHER, R et al. 1989 Biol Chem Hoppe-Seyler 370:503-510
The Organization of the Human Myelin Basic Protein Gene, Comparison with the

Mouse Gene.

Examiner
Initial**OTHER ART**

SU, X et al. 1991 J Neuroimmunol 34:181-190
Treatment Of Chronic Relapsing Experimental Allergic Encephalomyelitis With The Intravenous Administration Of Splenocytes Coupled To Encephalitogenic Peptide 91-103 Of Myelin Basic Protein.

TRAUGOTT, U et al. 1982 J Neurol Sci 56:65-73
Chronic Relapsing Experimental Autoimmune Encephalomyelitis, Treatment with Combinations of Myelin Components Promotes Clinical and Structural Recovery.

TUOHY V, et al. 1994 Neurochemical Research 19:935-944
Peptide Determinants of Myelin Proteolipid Protein (PLP) in Autoimmune Demyelinating Disease: A Review*

TUOHY, V et al. 1992 J Neuroimmunol 39:67-74
Myelin Proteolipid Protein: Minimum Sequence Requirements For Active Induction Of Autoimmune Encephalomyelitis In SWR/J And SJL/Mice.

UTZ, U et al. 1994 Proc. Natl. Acad. Sci USA 91:5567-5571
Heterogeneity Of T-Cell Receptor ~-Chain Complementarity-Determining Region 3 In Myelin Basic Protein-Specific T Cells Increases With Severity Of Multiple Sclerosis.

VAN DER VEEN, R et al. 1990 J Neuroimmunol 26:139-145
The Development And Characterization Of Encephalitogenic Cloned T Cells Specific For Myelin Proteolipid Protein

VAN DER VEEN, R et al. 1992 J Neuroimmunol 38:139-146
Immune Processing Of Proteolipid Protein By Subsets Of Antigen-Presenting Spleen Cells

VAN NOORT, J et al. 1994 J Chromatogr B 653:155-161
Fractionation Of Central Nervous System Myelin Proteins By Reversed-Phase High-Performance Liquid Chromatography.

VANDENBARK, A et al. 1989 Nature 341:541-544
Immunization With A Synthetic T-Cell Receptor V-Region Peptide Protects Against Experimental Autoimmune Encephalomyelitis.

VOSKUHL, R et al. 1993 J Neuroimmunol 42:187-192
T-Lymphocyte Recognition Of A Portion Of Myelin Basic Protein Encoded By An Exon Expressed During Myelination.

VOSKUHL, R et al. 1993 J Neuroimmunol 46:137-144
A Novel Candidate Autoantigen In A Multiplex Family With Multiple Sclerosis: Prevalence Of T-Lymphocytes Specific For An MBP Epitope Unique To Myelination.

Examiner
Initial

OTHER ART

— VOSKUHL, RR et al. 1994 J Immunol 153:4834-4844
HLA Restriction And TCR Usage Of T Lymphocytes Specific For A Novel Candidate Autoantigen, X2 MBP, In Multiple Sclerosis.

— WADA, K et al. 1992 Nucl Acids Res 20:(Supplement)2111-2118
Codon Usage Tabulated From The Genbank Genetic Sequence Data.

— WAUBEN, MH et al. 1994 J Immunol 150:4211-4220
Inhibition Of Experimental Autoimmune Encephalomyelitis By MHC Class II Binding Competitor Peptides Depends On The Relative MHC Binding Affinity Of The Disease-Inducing Peptide.

— WEIMBS, T et al. 1992 Biochemistry 31:12289-12296
Proteolipid Protein (PLP) Of CNS Myelin: Positions Of Free, Disulfide-Bonded, And Fatty Acid Thioester-Linked Cysteine Residues And Implications For The Membrane Topology Of PLP.

— WEINER, H et al. 1993 Science 259:1321-1324.
Double-Blind Pilot Trial Of Oral Tolerization With Myelin Antigens In Multiple Sclerosis.

— WHITHAM, R et al. 1991 J Immunol 147:101-107
Lymphocytes From SJL/J Mice Immunized With Spinal Cord Respond Selectively To A Peptide Of Proteolipid Protein And Transfer Relapsing Demyelinating Experimental Autoimmune Encephalomyelitis.

— WHITHAM, R et al. 1991 J Immunol 147:3803-3808
Location Of A New Encephalitogenic Epitope (Residues 43 To 64) In Proteolipid Protein That Induces Relapsing Experimental Autoimmune Encephalomyelitis In PL/J And (SJL X PL)F₁ Mice.

— WILLIAMS, DP et al. 1988 Nucl Acids Res 16:10453-10467
Design, Synthesis And Expression Of A Human Interleukin-2 Gene Incorporating The Codon Usage Bias Found In Highly Expressed *Escherichia coli* Genes.

— WUCHERPENNING, K et al. 1994 J Immunol 152:5581-5592
Clonal Expansion And Persistence Of Human T Cells Specific For An Immunodominant Myelin Basic Protein Peptide.

— YOON, 1993 Science 259:1263
MS Study Yields Mixed Results.

— ZAMVIL, et al. 1986. Nature 324, 258-260
T cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis.

Examiner
Initial

OTHER ART

- ZHANG J et al. 1992 Ann Neurol 32:330-338
Myelin Basic Protein-Specific T Lymphocytes in Multiple Sclerosis and Controls:
Precursor Frequency, Fine specificity, and Cytotoxicity.
- ZHANG, J et al. 1993 Science 261:1451-1454
MHC-Restricted Depletion Of Human Myelin Basic Protein-Reactive T Cells By T
Cell Vaccination.
- ZHANG, J et al. 1994 J Exp Med 179:973-984
Increased Frequency of Interleukin 2-responsive T Cells Specific for Myelin Basic
Protein and Proteolipid Protein in Peripheral Blood and Cerebrospinal fluid of
Patients with Multiple Sclerosis.